Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Vaxcyte, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 88 | 1 | 106 | +19 |
| Shares | 49.9M | 5.36K | 51.4M | +1.58M (+3.2%) |
| Value | $1.20B | $129.0K | $1.12B | −$84.6M (−7.0%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held Vaxcyte, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (5)
Institutions that held Vaxcyte, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| EcoR1 Capital, LLC | 1,304,741 | $31.5M |
| Bank of Montreal | 11,019 | $269.0K |
| Fred Alger Management, LLC | 9,677 | $234.0K |
| STRS Ohio | 5,100 | $123.0K |
| TCI Wealth Advisors, Inc. | 132 | $3.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Vaxcyte, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 5,357 | $129.0K |